Cobenfy (xanomeline-trospium): state of practice

Why this drug is a big deal

Every antipsychotic before 2024 blocks D2 receptors. Every single one. That's the mechanism that treats positive symptoms of psychosis, and it's also the mechanism that causes extrapyramidal symptoms, tardive dyskinesia, and prolactin elevation. Second-generation drugs added 5-HT2A antagonism to soften the motor picture, but the D2 blockade is still doing the antipsychotic work.

Cobenfy doesn't block D2 at all. It's a muscarinic acetylcholine receptor agonist, hitting M1 and M4 preferentially. The theory, worked out over decades by Karuna Therapeutics (now part of Bristol Myers Squibb), is that M4 agonism in the striatum indirectly reduces dopamine release without touching D2 receptors. That's why the drug can treat positive symptoms without causing the motor and prolactin side effects that come with dopamine blockade.

The mechanism has been chased since the 1990s. Xanomeline itself was studied for Alzheimer's cognitive symptoms and showed antipsychotic-like effects on behavioral disturbance, but the trials failed because the peripheral cholinergic side effects (nausea, vomiting, sweating, GI cramping) made it intolerable. The Karuna trick was to co-formulate xanomeline with trospium, a quaternary ammonium anticholinergic that doesn't cross the blood-brain barrier. Trospium blunts the peripheral muscarinic side effects while xanomeline still gets into the brain to do the antipsychotic work. That combination is what made the drug approvable.

What the trials showed

The three registrational trials are EMERGENT-1, EMERGENT-2, and EMERGENT-3. All three were 5-week randomized double-blind placebo-controlled trials in adults hospitalized with acute schizophrenia exacerbations.

EMERGENT-1 (Brannan et al., NEJM 2021) enrolled 182 patients. The primary endpoint was the change in Positive and Negative Syndrome Scale (PANSS) total score at week 5. Cobenfy separated from placebo by about 11 points, which is a large effect size for an antipsychotic trial. Positive symptoms improved, negative symptoms improved modestly, and there was no signal for weight gain, EPS, or prolactin elevation.

EMERGENT-2 (Kaul et al., Lancet 2024) and EMERGENT-3 (Kaul et al., JAMA 2024) replicated the finding in larger samples of 252 and 256 patients. PANSS separation was 9 to 10 points in both. The consistency across three trials is what made the FDA comfortable.

What the trials did not show: efficacy in patients with treatment-resistant schizophrenia (that's what the ARISE trial is testing, with results expected 2026), efficacy as an add-on to another antipsychotic (that's ADEPT), or long-term maintenance efficacy (that's the ongoing open-label extension). The label indication is adult schizophrenia, full stop, with no restriction to treatment-naive patients but no explicit endorsement for switching either.

Dosing and titration

The FDA-approved regimen starts at 50 mg xanomeline / 20 mg trospium twice daily for two days, then increases to 100 mg / 20 mg twice daily on day three, then to the target of 125 mg / 30 mg twice daily on day eight if tolerated. The titration is quick by antipsychotic standards but not aggressive.

Cobenfy is dosed twice daily on an empty stomach, at least one hour before or two hours after food. That's a real-world adherence issue. Patients with schizophrenia often have chaotic meal schedules, and the timing requirement is more restrictive than any other oral antipsychotic. In practice, most patients end up taking it first thing in the morning and at bedtime, which puts them near real meals but doesn't consistently hit the one-to-two hour window. The label is what it is, and the trial data comes from patients dosed per protocol, so it's worth being explicit with the patient about the timing.

The maximum dose is 125 / 30 mg twice daily. There is no head-to-head data comparing lower doses (100 mg / 20 mg twice daily) to the maximum, and clinical experience in early practice suggests some patients do fine at the middle dose with better tolerability. The label allows staying at 100 mg / 20 mg twice daily if that's what the patient tolerates.

Tolerability: the GI story

The trial adverse events were dominated by GI symptoms. Nausea in about 20 percent, constipation in 20 percent, vomiting in 15 percent, dyspepsia in 10 percent. Most were mild to moderate and clustered in the first two weeks. Discontinuation rates for GI side effects in the trials ran around 6 to 8 percent, meaning most patients pushed through.

In practice, three habits help. First, warning the patient explicitly that the first two weeks are the rough patch and it usually settles. That framing alone reduces dropout. Second, taking Cobenfy with a glass of water on an empty stomach and staying upright for at least 30 minutes seems to reduce nausea in clinical experience, even though it's not in the label. Third, being ready to slow the titration. There's no rule that day eight has to be 125 / 30 mg. A patient who's nauseated at 100 / 20 mg can stay there for another week or two, and many do fine on the middle dose long-term.

Constipation deserves a specific note because trospium is doing that. Prophylactic bulk-forming fiber (psyllium) plus adequate fluids from day one is easier than treating impaction on day thirty. If it's severe, PEG or lactulose. Stimulant laxatives are second-line.

What Cobenfy doesn't cause, based on the trial data: EPS, akathisia, tardive dyskinesia, weight gain, dyslipidemia, glucose dysregulation, prolactin elevation, sexual dysfunction, or sedation. Those are the reasons the drug is a genuine addition to the class, not just another me-too. The metabolic story matters most: 30 percent of schizophrenia patients on second-generation antipsychotics have metabolic syndrome, and premature cardiovascular death is the leading cause of shortened lifespan in this population. A drug that doesn't cause weight gain is not a small thing.

Contraindications and interactions

Cobenfy is contraindicated in urinary retention (trospium is doing that), gastric retention, uncontrolled narrow-angle glaucoma, moderate to severe hepatic impairment, and known hypersensitivity. Renal impairment (CrCl below 30) needs dose adjustment because trospium accumulates.

The interaction profile is different from other antipsychotics. Xanomeline is metabolized primarily by CYP2D6. Strong 2D6 inhibitors (fluoxetine, paroxetine, bupropion, duloxetine) raise xanomeline exposure and can worsen GI side effects. This matters because schizophrenia patients on antidepressants are common, and bupropion in particular is often added for negative symptoms or smoking cessation. Combining bupropion with Cobenfy isn't a hard stop, but it's a titration adjustment.

Trospium is a substrate for renal secretion. Metformin, which uses similar transporters, can raise trospium levels modestly. Not usually clinically meaningful but worth knowing when both drugs are on board.

Anticholinergic burden matters. Cobenfy plus a first-generation antipsychotic (chlorpromazine, thioridazine), plus benztropine, plus TCAs, plus scopolamine adds up quickly. Cognitive slowing, urinary retention, and constipation get worse. Best practice is to review the med list and consider whether other anticholinergics can come off.

Where Cobenfy fits right now

In practice, the drug has three roles in mid-2026.

The first is patients who cannot tolerate dopamine-blocking side effects. This includes patients with disabling EPS or akathisia on olanzapine, risperidone, or aripiprazole; patients with prior TD; patients with elevated prolactin; and patients who developed diabetes or significant weight gain on a second-generation agent. For any of these, Cobenfy is a genuine option and often the first thing to try after the offending drug is stopped.

The second is patients or families explicitly asking for an antipsychotic that doesn't cause weight gain. This request comes up more than it used to, and it's a legitimate one. The trial data supports the framing, and the conversation is easier when there's a real option to offer.

The third is treatment-resistant patients failing sequential antipsychotics. Clozapine is still the standard of care after two failed adequate trials, and Cobenfy is not a substitute for that. But some patients refuse clozapine, some have absolute contraindications, and some have tried it and can't tolerate it. Cobenfy is a reasonable next line before declaring true treatment resistance in those cases. The ARISE trial in treatment-resistant patients hasn't read out yet, so this remains extrapolation from the general schizophrenia data.

What Cobenfy is not, based on current evidence: it is not first-line for every newly diagnosed patient (risperidone and aripiprazole are cheaper, longer-established, and better understood in first-episode psychosis); it is not for bipolar mania, depression, or PTSD (no data, no indication); it is not for agitation or acute behavioral emergencies (the trial titration takes over a week to get to therapeutic dose); and it is not an option in patients with the specific contraindications listed above.

Coverage and cost

List price is roughly $22,500 per year, comparable to other newer branded antipsychotics but far above generic risperidone or aripiprazole. Insurance coverage in early 2026 varies. Medicare Part D has picked up Cobenfy on most formularies, usually with prior authorization requiring documentation of failed or intolerable prior antipsychotic trials. Commercial coverage is mixed. Bristol Myers Squibb runs a copay assistance program for commercially insured patients that brings the out-of-pocket cost to $10 per month, subject to annual maximums. For uninsured patients, the manufacturer's patient assistance program exists but is slow.

The practical implication for prescribers: expect a prior authorization on almost every prescription. Documenting the specific reason (prior EPS, prior weight gain of X pounds, prior prolactin elevation of Y ng/mL, prior D2-related hyperprolactinemia symptoms) makes the PA go through faster.

Common questions

Is Cobenfy better than second-generation antipsychotics? The trial data shows comparable efficacy on positive symptoms with a genuinely different side effect profile. It's not clearly more effective than olanzapine or risperidone for positive symptoms, and it hasn't been tested head-to-head against them. What it does offer is efficacy without weight gain, without EPS, without prolactin, and without sedation. Whether that's "better" depends on which side effects a patient is trying to avoid. For a patient with disabling EPS on risperidone or 30 pounds of weight gain on olanzapine, Cobenfy is a straightforward improvement. For a patient doing well on aripiprazole with no side effects, there's no reason to switch.

How long until it works? The trials showed PANSS separation from placebo by week two, with continued improvement through week five. That's a similar timeline to any oral antipsychotic. In practice, expect two to four weeks for meaningful improvement in positive symptoms if the drug is going to work.

Can Cobenfy be used with clozapine or another antipsychotic? The label does not specifically address combination therapy. The ADEPT trial is testing xanomeline-trospium as an adjunct to a stable dose of another antipsychotic, and results are expected in 2026. Off-label combination is happening in clinical practice, especially for patients who partially responded to clozapine or another agent. There's no efficacy data yet, and the anticholinergic burden goes up when combining with drugs that have any muscarinic activity of their own.

Does Cobenfy help negative symptoms? The trial data showed statistically significant but clinically modest improvement in negative symptoms, similar to what second-generation antipsychotics show. It is not a specific negative-symptom drug. Anyone marketing it that way is overstating the evidence.

What about cognition? Xanomeline was originally developed for Alzheimer's cognitive symptoms and showed procognitive signals in early Alzheimer's trials. In the EMERGENT schizophrenia trials, cognition was a secondary outcome, and there was a modest signal favoring Cobenfy over placebo. The signal is real but the effect size is small, and it's not enough to prescribe Cobenfy specifically for cognitive symptoms. Whether it becomes a legitimate procognitive option depends on longer-term data still to come.

Is Cobenfy safe in pregnancy? There is no human pregnancy data. Animal studies at high doses showed developmental effects. The label describes the general risk of untreated maternal psychosis and the lack of specific human data, and defers to individual risk-benefit discussion. For a patient already stable on Cobenfy who becomes pregnant, staying on the drug is a reasonable option after informed discussion, especially if prior antipsychotics caused significant problems. For a patient starting new treatment during pregnancy, better-studied options (olanzapine, quetiapine) are still first-line in most consensus guidelines.

Should I switch a stable patient to Cobenfy? Not if the current antipsychotic is working and side effects are manageable. Switching to a genuinely different mechanism carries the risk of losing the response, and Cobenfy takes weeks to reach effective levels. The switching indication is when the current drug's side effects are causing real problems (metabolic, motor, sexual, prolactin) or when adherence is poor and the family sees Cobenfy's profile as a reason to try again. For a stable patient with no side effect complaints, "if it ain't broke" applies.

How is Cobenfy monitored? Standard baseline labs (CBC, CMP, lipid panel, HbA1c) still apply, mostly because the patient has schizophrenia and needs cardiovascular monitoring regardless of the drug. Cobenfy itself has no required lab monitoring. No ANC monitoring, no ECG requirement, no metabolic monitoring schedule specific to the drug. That's a significant workflow simplification. What does need clinical follow-up: urinary retention symptoms (especially in older men with BPH), constipation, cognitive complaints suggesting anticholinergic burden, and the usual antipsychotic outcomes (symptom trajectory, function, treatment adherence).

What's next

Three pieces of data will change the picture over the next 18 months. The ARISE trial in treatment-resistant schizophrenia reads out in 2026 and will settle whether Cobenfy has a role for patients failing multiple antipsychotics before clozapine. The ADEPT trial in adjunctive use reads out in 2026 as well. And the open-label extension data on long-term safety past one year will accumulate. Anything discovered late in an open-label extension (rare adverse events, tolerability drift, effectiveness maintenance) tends to be the thing that shapes real-world use.

Off-label use in Alzheimer's-related psychosis and behavioral disturbance is happening in early practice, borrowed from the older xanomeline dementia data. This is not label indication, and no controlled trial has read out yet, but the rationale is coherent. If any of the ongoing Alzheimer's programs read out positively, the drug's use in dementia may become as substantial as its use in schizophrenia.

The next muscarinic antipsychotic in development is emraclidine (Cerevel/AbbVie), a selective M4 positive allosteric modulator. Its Phase 2 program had mixed results in late 2024 and 2025, and its trajectory is unclear. If it or another selective M4 drug succeeds, the class starts to look like a real alternative to D2 blockade rather than a single novel drug.

Sources

• Brannan SK, Sawchak S, Miller AC, et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384(8):717-726.
• Kaul I, Sawchak S, Correll CU, et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial (EMERGENT-3). JAMA Psychiatry. 2024.
• Kaul I, Sawchak S, Walling DP, et al. Efficacy and safety of xanomeline-trospium in schizophrenia: a randomized clinical trial (EMERGENT-2). Lancet. 2024.
• Cobenfy (xanomeline and trospium chloride) capsules, for oral use. Prescribing information. Bristol Myers Squibb; approved September 26, 2024. Available via DailyMed.
• Correll CU, et al. Practical considerations for the use of xanomeline-trospium in schizophrenia. J Clin Psychiatry, 2025 (open-access practice guidance).
• Sauder C, Allen LA, Baker E, et al. Effectiveness of xanomeline-trospium on cognitive impairment in schizophrenia: pooled analysis. Schizophrenia Research: Cognition. 2024.